文献速递淋巴瘤

液体活检在结外NK/T细胞淋巴瘤中的应用:cfDNA基因分型与监测的前瞻性分析

Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring.
PubMed 文献 · Blood Adv · 2021-01-01

该前瞻性研究对高危结外NK/T细胞淋巴瘤患者进行肿瘤组织与纵向血浆cfDNA的靶向测序,评估配对基线肿瘤与cfDNA基因分型的一致性及动态cfDNA监测的预测价值。结果显示血浆cfDNA可反映肿瘤突变谱,快速清除NKTCL相关突变者完全缓解率更高、生存更优,治疗前低cfDNA浓度与良好生存相关。

要点

  • 血浆cfDNA对肿瘤活检突变检测敏感性为72.4%,并可发现活检未检出突变。
  • 血浆NKTCL相关突变快速清除者完全缓解率80.0% vs 0%(P=.004)。
  • 快速清除者1年PFS率79.0% vs 20.0%(P=.002),生存更优。

核心结论

  • cfDNA可反映NKTCL肿瘤活检的基因改变,无创动态血浆cfDNA监测有望用于追踪疗效和生存结局。

研究设计与样本

  • 前瞻性队列研究,对24例高危NKTCL患者治疗前肿瘤组织及系列纵向血浆样本行靶向下一代测序。
  • 另纳入23例高危NKTCL患者作为验证队列验证结果。

主要发现

  • 24例高危NKTCL患者中19例(79.2%)在肿瘤和/或血浆cfDNA中检出31个基因的59个体细胞变异。
  • 血浆cfDNA检测治疗前肿瘤活检所识别体细胞变异的敏感性为72.4%。
  • 血浆cfDNA还可识别肿瘤活检中未检出的突变,并在23例验证队列中得到验证。
  • 血浆NKTCL相关突变快速清除者完全缓解率为80.0% vs 0%(P=.004),1年PFS率为79.0% vs 20.0%(P=.002)。
  • 治疗前低cfDNA浓度与 favorable 生存相关:1年PFS率90.0% vs 36.4%(P=.012)。

临床怎么用

  • 对难以获取肿瘤组织的NKTCL患者,可考虑血浆cfDNA基因分型作为组织活检的补充。
  • 动态监测血浆cfDNA中NKTCL相关突变清除情况,可辅助评估治疗反应和生存预后。
  • 治疗前cfDNA浓度低可能提示较好生存结局,可作为预后参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Satisfactory tumor material is often hard to obtain for molecular analysis in extranodal natural killer (NK)/T-cell lymphoma (NKTCL) at present. However, the accuracy and utility of circulating cell-free DNA (cfDNA) genotyping have not been adequately assessed in NKTCL. We therefore performed targeted next-generation sequencing on tumor tissues and a series of longitudinal plasma samples prospectively collected from a cohort of high-risk NKTCL patients. Concordance of genotyping results of paired baseline tumor and cfDNA and the predictive value of dynamic cfDNA monitoring were evaluated. At baseline, 59 somatic variants in 31 genes were identified in tumor and/or plasma cfDNA among 19 out of 24 high-risk NKTCL patients (79.2%). Plasma cfDNA had a sensitivity of 72.4% for detection of somatic variants identified in tumor biopsies before treatment. Plasma cfDNA also allowed the identification of mutations that were undetectable in tumor biopsies. These results were also verified in a validation cohort of an additional 23 high-risk NKTCL patients. Furthermore, longitudinal analysis showed that patients with rapid clearance of NKTCL-related mutations from plasma had higher complete remission rates (80.0% vs 0%; P = .004) and more favorable survival (1-year progression-free survival [PFS] rate, 79.0% vs 20.0%; P = .002) compared with those with persisting or emerging mutations in plasma. In addition, low cfDNA concentration before treatment was associated with favorable survival outcome for patients with NKTCL (1-year PFS, 90.0% vs 36.4%; P = .012). In conclusion, cfDNA mirrors tumor biopsy for detection of genetic alterations in NKTCL and noninvasive dynamic plasma cfDNA monitoring might be a promising approach for tracking response and survival outcome for patients with NKTCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Qi F, Cao Z, Chen B, et al. Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring. Blood Adv. 2021. PMID: 34047776. doi:10.1182/bloodadvances.2020001637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。